BCR and sarcoma: Indeed, research has shown that just a single i.v. dose of saracatinib—a similar dual Bcr—Abl/Src inhibitor to bosutinib, inhibits pulmonary metastasis when administered shortly after i.v. injection of sarcoma cells into a murine model [26].